Skip to content
Conestat alfa
Ruconest (conestat alfa) is a protein pharmaceutical. Conestat alfa was first approved as Ruconest on 2010-10-28. It has been approved in Europe to treat hereditary angioedemas.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
ruconestBiologic Licensing Application2022-10-24
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B06: Other hematological agents in atc
— B06A: Other hematological agents in atc
— B06AC: Drugs used in hereditary angioedema
— B06AC04: Conestat alfa
HCPCS
No data
Clinical
Clinical Trials
61 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hereditary angioedemasD054179EFO_000413129131123
Hereditary angioedema types i and iiD056829222117
Covid-19D000086382U07.1—1—1—2
Common variable immunodeficiencyD017074EFO_0000367D83———1—1
AsthmaD001249EFO_0000270J45———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AngioedemaD000799EFO_0005532T78.3—34——5
Inborn genetic diseasesD030342EFO_0000508—32——4
InflammationD007249——2—13
SepsisD018805A41.9——2——2
EndotoxemiaD019446——1—12
Multiple organ failureD009102EFO_1001373——1—12
Innate immunityD007113——1——1
Wounds and injuriesD014947T14.8——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Reperfusion injuryD01542722———3
Renal insufficiencyD051437HP_0000083N1921———2
Kidney transplantationD01603012———2
Chronic kidney failureD007676EFO_0003884N18.622———2
Acute kidney injuryD058186HP_0001919N17—2———2
Graft rejectionD006084—2———2
Ischemic strokeD00008324211———2
Coronavirus infectionsD018352EFO_0007224B34.2—1———1
Chronic renal insufficiencyD051436N1811———1
Traumatic brain injuriesD000070642S06—1———1
Show 3 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuromyelitis opticaD009471EFO_0004256G36.01————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCONESTAT ALFA
INNconestat alfa
Description
Ruconest (conestat alfa) is a protein pharmaceutical. Conestat alfa was first approved as Ruconest on 2010-10-28. It has been approved in Europe to treat hereditary angioedemas.
Classification
Protein
Drug classenzyme inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2108350
ChEBI ID—
PubChem CID—
DrugBankDB06404
UNII ID5QS67N4551 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Ruconest - Pharming
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 289 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,555 adverse events reported
View more details